-
31 votes
-
US FDA finally moves to scrutinize specialized health screenings
14 votes -
A US FDA-approved device offers a new treatment for tinnitus
32 votes -
The influencer who “reverses” Lupus with smoothies. Psychiatrist Brooke Goldner makes extraordinary claims about incurable diseases. It’s brought her a mansion, a Ferrari, and a huge social following.
18 votes -
US Food and Drug Administration issues report claiming marijuana has legitimate medical uses - proposes rescheduling
51 votes -
Single dose of clinical-grade LSD provides immediate and lasting relief from anxiety, wins approval for phase III trials
69 votes -
Elon Musk's Neuralink implants brain chip in first human
35 votes -
How two US pharmacists figured out that oral phenylephrine decongestants don’t work
32 votes -
US FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR
49 votes -
US court orders Balance of Nature to stop sales of supplements after FDA lawsuits
7 votes -
Phenylephrine, a common decongestant in medicines is no better than a placebo when taken orally, says a US FDA advisory panel
by Wes Davis A key cold medicine ingredient is basically worthless The FDA’s 16-member advisory panel unanimously voted yesterday that oral phenylephrine, a common active ingredient in cold...
by Wes Davis
A key cold medicine ingredient is basically worthless
The FDA’s 16-member advisory panel unanimously voted yesterday that oral phenylephrine, a common active ingredient in cold medications, is no better than a placebo for treating congestion.
Link to the article
The call by the panel sets up potential FDA action that could force the removal of certain over-the-counter medications containing the ingredient — including certain formulations of Mucinex, Sudafed, Tylenol, and NyQuil — from store shelves.
But FDA may hold off for many months, pending contested findings by drug makers and other considerations.Data
Newer data from studies the panel says are more consistent with modern clinical trial standards showed phenylephrine simply “was not significantly different from placebo” in the recommended dosage, including trials from 2007 that the FDA had reviewed when considering the drug after a citizen petition prompted it to do so.
Bioavailability
The panel cited the drug’s low bioavailability, a term referring to qualities that allow the drug to be absorbed by the human body, as the main reason the drug should be removed from the market.
Jennifer Schwartzott said the drug “should have been removed from the market a long time ago,” while Dr. Stephen Clement said that although the drug itself isn’t dangerous, its usage by patients should be considered unsafe because it potentially delays actual treatment of disease symptoms.
Alternative
The panel cited pseudoephedrine as an effective alternative though while it’s technically available without a prescription, you must talk to a pharmacist to get it because, in large quantities, it can be used to make methamphetamines.
50 votes -
Florida surgeon general rejects FDA guidance, urges people under 65 not to get Covid booster
26 votes -
US Food and Drug Administration approves new Covid vaccine boosters
21 votes -
US Food and Drug Administration approves first postpartum depression pill in the US
19 votes -
United States FDA says aspartame is safe, disagreeing with World Health Organization finding
37 votes -
First over-the-counter birth control pill gets US FDA approval
58 votes -
US FDA approving drugs at breakneck speed
9 votes